HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John R Basile Selected Research

CD100 antigen

8/2021Retraction notice to <Recruitment of Tiam1 to Semaphorin 4D activates Rac and enhances proliferation, invasion and metastasis in oral squamous cell carcinoma> <[Neoplasia 19 (2016) 65-74]>.
1/2020Retraction Note to: Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression.
1/2017Recruitment of Tiam1 to Semaphorin 4D Activates Rac and Enhances Proliferation, Invasion, and Metastasis in Oral Squamous Cell Carcinoma.
1/2017Characterization of the Effects of Semaphorin 4D Signaling on Angiogenesis.
1/2016Semaphorin 4D Promotes Skeletal Metastasis in Breast Cancer.
1/2014The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4.
9/2012Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression.
8/2012The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma.
1/2012Plexin-B1 and semaphorin 4D cooperate to promote perineural invasion in a RhoA/ROK-dependent manner.
1/2011Plexin-B1 activates NF-κB and IL-8 to promote a pro-angiogenic response in endothelial cells.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John R Basile Research Topics

Disease

24Neoplasms (Cancer)
08/2021 - 07/2003
11Squamous Cell Carcinoma of Head and Neck
08/2021 - 06/2006
7Neoplasm Metastasis (Metastasis)
08/2021 - 06/2006
6Carcinoma (Carcinomatosis)
12/2017 - 06/2006
3Kaposi Sarcoma (Kaposi's Sarcoma)
11/2017 - 08/2010
2Melanoma (Melanoma, Malignant)
10/2019 - 01/2008
2Head and Neck Neoplasms (Head and Neck Cancer)
02/2014 - 03/2013
2Pathologic Neovascularization
01/2014 - 06/2008
2Hypoxia (Hypoxemia)
08/2012 - 11/2009
1Odontogenic Cysts (Keratocyst)
05/2021
1Periodontal Cyst
05/2021
1Cysts
05/2021
1Heart Arrest (Cardiac Arrest)
10/2019
1Dyspnea (Shortness of Breath)
10/2019
1Myocarditis (Carditis)
10/2019
1Hyperlipidemias (Hyperlipidemia)
02/2018
1Xanthomatosis (Xanthoma)
02/2018
1Psoriasis (Pustulosis Palmaris et Plantaris)
02/2017
1Lymphoma (Lymphomas)
01/2017
1Pathologic Processes
01/2017
1Mucocele
06/2016
1Breast Neoplasms (Breast Cancer)
01/2016
1Lymphadenitis (Adenitis)
08/2014
1Type 2 Diabetes Mellitus (MODY)
03/2013
1Carcinogenesis
03/2013
1Edema (Dropsy)
05/2011
1Anthrax
01/2008
1Granular Cell Tumor
07/2003
1Inflammation (Inflammations)
02/2003

Drug/Important Bio-Agent (IBA)

13CD100 antigenIBA
08/2021 - 06/2006
10Proteins (Proteins, Gene)FDA Link
01/2017 - 06/2006
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2020 - 05/2011
5Semaphorins (Semaphorin)IBA
01/2017 - 06/2008
4Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2012 - 06/2006
3plexinIBA
01/2014 - 01/2011
3Oxygen (Dioxygen)IBA
08/2012 - 06/2006
2ParaffinIBA
05/2021 - 08/2014
2Angiogenic ProteinsIBA
11/2017 - 01/2017
2Interleukin-8 (Interleukin 8)IBA
01/2016 - 01/2011
2Biological ProductsIBA
02/2014 - 05/2013
2AngiopoietinsIBA
05/2011 - 08/2010
1Caspase 3 (Caspase-3)IBA
05/2021
1IpilimumabIBA
10/2019
1NivolumabIBA
10/2019
1Immune Checkpoint InhibitorsIBA
10/2019
1SteroidsIBA
10/2019
1LipidsIBA
02/2018
1AmylasesFDA Link
12/2017
1GlycogenIBA
12/2017
1Coloring Agents (Dyes)IBA
12/2017
1Angiopoietin-2IBA
11/2017
1Adalimumab (Humira)FDA Link
02/2017
1GTP Phosphohydrolases (GTPases)IBA
01/2017
1Cysteine (L-Cysteine)FDA Link
01/2017
1APTIBA
06/2016
1MucinsIBA
06/2016
1EndoglinIBA
08/2014
1Formaldehyde (Formol)FDA Link
08/2014
1Annexin A2 (Annexin II)IBA
08/2014
1Calcium-Binding ProteinsIBA
08/2014
1Phosphotransferases (Kinase)IBA
02/2014
1p38 Mitogen-Activated Protein KinasesIBA
02/2014
1SB 203580IBA
02/2014
1MitogensIBA
02/2014
1Angiopoietin-Like Protein 4IBA
01/2014
1Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA
01/2014
1cadherin 5IBA
01/2014
1Antiviral Agents (Antivirals)IBA
05/2013
1Pharmacologic ActionsIBA
03/2013
1TOR Serine-Threonine KinasesIBA
03/2013
1Metformin (Glucophage)FDA LinkGeneric
03/2013
1CarcinogensIBA
03/2013
1BiguanidesIBA
03/2013
1Mechanistic Target of Rapamycin Complex 1IBA
03/2013
1AMP-Activated Protein KinasesIBA
03/2013
1Blocking AntibodiesIBA
08/2012
1Transcription Factors (Transcription Factor)IBA
08/2012
1Neutralizing AntibodiesIBA
08/2012
1rho-Associated KinasesIBA
01/2012
1LigandsIBA
01/2012
1CytokinesIBA
05/2011
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
08/2010
1RNA (Ribonucleic Acid)IBA
11/2009
1Glucose (Dextrose)FDA LinkGeneric
11/2009
1Virulence Factors (Pathogenicity Factors)IBA
01/2008
1anthrax toxin receptorsIBA
01/2008
1Matrix Metalloproteinases (MMPs)IBA
01/2008
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2008
1Metalloproteases (Metalloproteinases)IBA
03/2007
1Matrix Metalloproteinase 14 (MT1-MMP)IBA
03/2007
1Small Interfering RNA (siRNA)IBA
06/2006
1AntibodiesIBA
06/2006
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2003

Therapy/Procedure

5Therapeutics
01/2014 - 07/2003
1Defibrillators (Defibrillator)
10/2019
1Immunotherapy
10/2019
1Chemoprevention
03/2013
1Radiotherapy
08/2012
1Drug Therapy (Chemotherapy)
08/2012